Transient leukemia in a newborn without Down syndrome: case report and review of the literature.

[en] Transient neonatal leukemia occurs almost exclusively in Down syndrome babies. We report here the unusual case of a newborn without Down syndrome who presented neonatal transient leukemia and who achieved spontaneously complete remission. Trisomy 21 and GATA1 mutation were both present in leukemic cells. While close follow-up is advised since true leukemia may develop later, the patient is still in remission for 2.5 years. We performed a literature review of 15 other similar cases. Conclusion: Our case of transient leukemia without Down syndrome and the literature review highlight the important role of trisomy 21 and GATA1 mutation in the development of transient neonatal leukemia.

Disciplines :

Genetics & genetic processes

Author, co-author :

Rozen, Laurence

Huybrechts, Sophie

Dedeken, Laurence

Heijmans, Catherine

Dessars, Barbara

Heimann, Pierre

LAMBERT, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Génétique

Noubouossie, Denis F.

Ferster, Alina

Demulder, Anne

Language :

English

Title :

Transient leukemia in a newborn without Down syndrome: case report and review of the literature.

Publication date :

2013

Journal title :

European Journal of Pediatrics

ISSN :

0340-6199

eISSN :

1432-1076

Publisher :

Springer, Germany

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 17 April 2014

Statistics

Number of views

49 (3 by ULiège)

Number of downloads

1 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Brissette MD, Duval-Arnould BJ, Gordon BG, Cotelingam JD (1994) Acute megakaryoblastic leukemia following transient myeloproliferative disorder in a patient without Down syndrome. Am J Hematol 47:316–319
Bull MJ, Committee on Genetics (2011) Health supervision for children with Down syndrome. Pediatrics 128:393–406
Carpenter E, Valverde-Garduno V, Sternberg A, Mitchell C, Roberts I, Vyas P, Vora A (2005) GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder. Br J Haematol 128:548–551
Cushing T, Clericuzio CL, Wilson CS, Taub JW, Ge Y, Reichard KK, Winter SS (2006) Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder. J Pediatr 148:687–689
Elagib KE, Racke FK, Mogass M, Khetawat R, Delehanty LL, Goldfarb AN (2003) RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood 101:4333–4341
Gamis AS, Alonzo TA, Gerbing RB, Hilden JM, Sorrell AD, Sharma M, Loew TW, Arceci RJ, Barnard D, Doyle J, Massey G, Perentesis J, Ravindranath Y, Taub J, Smith FO (2011) Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from Children’s Oncology Group Study A2971. Blood 118:6752–6759
Gamis AS, Hilden JM (2002) Transient myeloproliferative disorder, a disorder with too few data and many unanswered questions: does it contain an important piece of the puzzle to understanding hematopoiesis and acute myelogenous leukemia? J Pediatr Hematol Oncol 24:2–5
Gurbuxani S, Vyas P, Crispino JD (2004) Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood 103:399–406
Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A (2003) GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood 101:4301–4304
Hitzler J, Zipursky A (2005) Gata1 mutations as clonal markers of minimal residual disease in acute megakaryoblastic leukemia of Down syndrome—a new tool with significant potential applications. Leuk Res 29:1239–1240
Inaba H, Londero M, Maurer SH, Onciu M, Ge Y, Taub JW, Rubnitz JE, Raimondi SC (2011) Acute megakaryoblastic leukemia without GATA1 mutation after transient myeloproliferative disorder in an infant without Down syndrome. J Clin Oncol 29:e230–e233
Ivan DL, Cromwell P (2013) Clinical practice guidelines for management of children with Down syndrome: part I and II. J Pediatr Health Care
Izraeli S (2004) Leukaemia—a developmental perspective. Br J Haematol 126:3–10
Kempski HM, Craze JL, Chessells JM, Reeves BR (1998) Cryptic deletions and inversions of chromosome 21 in a phenotypically normal infant with transient abnormal myelopoiesis: a molecular cytogenetic study. Br J Haematol 103:473–479
Lange B (2000) The management of neoplastic disorders of haematopoiesis in children with Down’s syndrome. Br J Haematol 110:512–524
Magalhães IQ, Splendore A, Emerenciano M, Córdoba MS, Córdoba JC, Allemand PA, Ferrari I, Pombo-de-Oliveira MS (2005) Transient neonatal myeloproliferative disorder without Down syndrome and detection of GATA1 mutation. J Pediatr Hematol Oncol 27:50–52
Moritake H, Yamada A, Kimoto Y, Sawa D, Shimonodan H, Nunoi H (2012) Acute megakaryoblastic leukemia and severe pulmonary fibrosis in a child with Down syndrome: successful treatment with ultra low-dose cytarabine using GATA1 mutation to monitor minimal residual disease. Am J Hematol:447–450
Polski JM, Galambos C, Gale GB, Dunphy CH, Evans HL, Batanian JR (2002) Acute megakaryoblastic leukemia after transient myeloproliferative disorder with clonal karyotype evolution in a phenotypically normal neonate. J Pediatr Hematol Oncol 24:50–54
Pine SR, Guo Q, Yin C, Jayabose S, Levendoglu–Tugal O, Ozkaynak MF, Sandoval C (2005) Gata1 mutations as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome. Leuk Res 29:1353–1356
Richards M, Welch J, Watmore A, Readett D, Vora AJ (1998) Trisomy 21 associated transient neonatalmyeloproliferation in the absence of Down’s syndrome. Arch Dis Child Fetal Neonatal Ed 79:F215–F217
Roizen NJ, Patterson D (2003) Down’s syndrome. Lancet 361:1281–1289
Roy A, Roberts I, Vyas P (2012) Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome. Semin Fetal Neonatal Med 17:196–201
Solky BA, Yang FC, Xu X, Levins P (2004) Transient myeloproliferative disorder causing a vesiculopustular eruption in a phenotypically normal neonate. Pediatr Dermatol 21:551–554
Tsai M-H, Hou J-W, Yang C-P, Yang P-H, Chu S-M, Hsu J-F, Chiang M-C, Huang H-R (2011) Transient myeloproliferative disorder and GATA1 mutation in neonates with and without Down syndrome. Indian J Pediatr 78:826–832
Taub JW, Ravindranath Y (2002) Down syndrome and the transient myeloproliferative disorder: why is it transient? J Pediatr Hematol Oncol 24:6–8
Van den Berg H, Hopman AH, Kraakman KC, de Jong D (2004) Spontaneous remission in congenital leukemia is not related to (mosaic) trisomy 21: case presentation and literature review. Pediatr Hematol Oncol 21:135–144
Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM, Crispino JD (2002) Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 32:148–152
Weijerman ME, de Winter JP (2010) The care of children with Down syndrome. Eur J Pediatr 169:1445–1452
Williams BA, Meyn MS, Hitzler JK (2011) Transient leukemia in newborns Down syndrome: diagnostic and management challenges. J Pediatr Hematol Oncol 33:261–263
Wolfe LC, Weinstein HJ, Ferry JA (2003) Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 19–200. A five-day-old girl with leukocytosis and a worsening rash from birth. N Engl J Med 348:2557–2566
Worth LL, Zipursky A, Christensen H, Tubergen D (1999) Transient leukemia with extreme basophilia in a phenotypically normal infant with blast cells containing a pseudodiploid clone, 46, XY i(21)(q10). J Pediatr Hematol Oncol 21:63–66
Yanase K, Kato K, Katayama N, Mouri Y, Kobayashi C, Shiono J, Abe M, Yoshimi A, Koike K, Arai J-I et al (2010) Transient abnormal myelopoiesis in a cytogenetically normal neonate. Int J Hematol 92:527–530
Zipursky A, Brown E, Christensen H, Sutherland R, Doyle J (1997) Leukemia and/or myeloproliferative syndrome in neonates with Down syndrome. Semin Perinatol 21:97–101
Zipursky A, Poon A, Doyle J (1992) Leukemia in Down syndrome: a review. Pediatr Hematol Oncol 9:139–149